Furthermore, CDK12 mutations in melanoma are already known to impact immunotherapy response [61] Analysis of Reduced CDK12/13 expression in metastatic melanoma patients significantly predicted improved survival and response to immune checkpoint blockade [61]. The gene discussed is CDK12; the disease is metastatic melanoma.